Alterity Therapeutics Ltd 6-K, filed Nov 29, 2023
Alterity Therapeutics Ltd (ATHE)
About this 6-K
Alterity Therapeutics Ltd filed this 6-K on November 29, 2023.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2023
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
| 99.1 | Notice Under Section 708A |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | ||
| By: | /s/ Geoffrey P. Kempler | |
| Geoffrey P. Kempler | ||
| Chairman | ||
Date: November 29, 2023
2
Exhibit 99.1
| ASX ANNOUNCEMENT | 29 November 2023 |
Notice Under Section 708A(5)(e) of the Corporations Act
This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).
| Details of securities issued | |
| Type | Shares |
| Class/Description | Fully paid ordinary shares |
| ASX Code | ATH |
| Date of Issue | 29 November 2023 |
| Number Issued | 362,462,762 |
The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act that:
| 1. | the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; |
| 2. | as at the date of this notice, the Company has complied with: |
| (i) | the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and |
| (ii) | sections 674 and 674A of the Corporations Act; and |
| 3. | as at the date of this notice there is no information to be disclosed which is ‘excluded information’ (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company. |
Phillip Hains
Company Secretary
Alterity Therapeutics Limited ACN 080 699 065
Level 3, 62 Lygon Street Carlton Victoria 3053 Australia
www.alteritytherapeutics.com